entertainment -WSS

entertainment

author：explore 2025-09-30 17:43:53 - browse：2

a liver made up by geometric shapes – biotech coverage from STAT — Adobe

LONDON — A drug in development as a weight loss treatment succeeded in a Phase 2 study in a serious liver condition, its developers said Monday, as the competition in the broader obesity medicine field pushes ahead.

The drug, survodutide, is being developed by the privately held German firm Boehringer Ingelheim and the Danish biotech Zealand Pharma. Zealand’s share price has doubled over the past year over the potential of the drug, and on Monday morning, shares jumped another 25%.

In the study, 83% of patients with a condition called MASH and who were treated with survodutide saw significant improvements in their disease compared to 18% of those who received placebo. The study met its primary endpoint of improvements in MASH after 48 weeks without the worsening of fibrosis, a scarring of the liver, the companies said. Secondary endpoints were also met, including an improvement in fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Prescription digital therapeutics are key to pharma’s future

focus

hotspot

WSS

Why medical students are struggling with mental health

Congress must reauthorize a committee to support older Americans

Vertex cell therapy lets patients with type 1 diabetes stop insulin

What affirmative action's end means to a medical student

What affirmative action's end means to a medical student

Prescription digital therapeutics are key to pharma’s future

hotspot

entertainment

entertainment

Continuity nursing helped my family in our darkest PICU moments

Weight loss drug costs may need more research, senator suggests

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Crowdfunding for unproven stem cell procedures spreads misinformation

Hepatitis C has a cure — but many Americans still lack access to it

Dexcom's push to bring CGM to type 2 diabetes patients

Tori Bowie and the unacceptable rates of Black maternal death

Undocumented workers face uncertainty as immigration law takes effect in Florida

Alkermes shareholders re

'Screen and refer' systems are hurting patients

leisure time

Surge of respiratory disease in China has likely explanation

Ransomware attacks on hospitals: Study outlines patient impact

Lupron, used to halt puberty in children, may cause lasting health problems

Crowdfunding for unproven stem cell procedures spreads misinformation

Fatty liver disease was alleviated by Lilly’s ‘triple

Hubble vs. James Webb telescope images: See the difference

focus

Wikipedia

hotspot

knowledge